Table 1.
Overall Study Cohort Characteristics for Patients With Ebola Virus Disease
| Characteristic | No. (%) |
|---|---|
| Age, y, mean (SD) | 30.5 (18.7) |
| Sex | |
| Female | 252 (59.4) |
| Male | 171 (40.3) |
| ETU location | |
| Bong County, Liberia | 129 (30.4) |
| Margibi County, Liberia | 5 (1.2) |
| Kambia District, Sierra Leone | 33 (7.8) |
| Port Loco District, Sierra Leone | 148 (34.9) |
| Bombali District, Sierra Leone | 109 (25.7) |
| Cycle threshold value | |
| Low (≤22) | 159 (37.5) |
| High (>22) | 122 (28.8) |
| Missing | 143 (33.7) |
| Patients with characteristic during ETU admission | |
| Anorexia | 342 (80.7) |
| Any bleeding | 198 (46.9) |
| Coma | 41 (9.9) |
| Confusion | 56 (13.4) |
| Diarrhea | 362 (85.6) |
| Dysphagia | 248 (58.7) |
| Dyspnea | 204 (48.3) |
| Fever | 325 (76.7) |
| Stomach pain | 326 (76.9) |
| Vomiting | 325 (76.7) |
| Patients receiving treatment during ETU admission | |
| Acetaminophen | 410 (96.7) |
| Artemether | 19 (4.5) |
| Artemether-lumefantrine | 379 (89.6) |
| Artesunate | 24 (5.7) |
| Cefixime | 388 (91.7) |
| Ceftriaxone | 97 (22.9) |
| Ciprofloxacin | 30 (7.3) |
| Metoclopramide | 122 (28.8) |
| Metronidazole | 17 (4.2) |
| Multivitamins | 312 (73.8) |
| Omeprazole | 395 (93.2) |
| Ondansetron | 175 (41.3) |
| Oral rehydration solution | 404 (95.5) |
| Promethazine | 8 (2.1) |
| Vitamin A | 357 (84.2) |
| Vitamin C | 398 (93.9) |
| Zinc sulphate | 55 (13.0) |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: ETU, Ebola treatment unit; SD, standard deviation.